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ARTICLE
Host-mediated selection impacts the diversity of
Plasmodium falciparum antigens within infections
Angela M. Early1,2, Marc Lievens3, Bronwyn L. MacInnis1,2, Christian F. Ockenhouse4, Sarah K. Volkman1,2,5,
Samuel Adjei6, Tsiri Agbenyega6, Daniel Ansong6, Stacey Gondi7, Brian Greenwood8, Mary Hamel9,
Chris Odero9, Kephas Otieno9, Walter Otieno7, Seth Owusu-Agyei8,10,11, Kwaku Poku Asante10,
Hermann Sorgho12, Lucas Tina7, Halidou Tinto12, Innocent Valea12, Dyann F. Wirth1,2 & Daniel E. Neafsey1,2
Host immunity exerts strong selective pressure on pathogens. Population-level genetic
analysis can identify signatures of this selection, but these signatures reﬂect the net selective
effect of all hosts and vectors in a population. In contrast, analysis of pathogen diversity
within hosts provides information on individual, host-speciﬁc selection pressures. Here, we
combine these complementary approaches in an analysis of the malaria parasite Plasmodium
falciparum using haplotype sequences from thousands of natural infections in sub-Saharan
Africa. We ﬁnd that parasite genotypes show preferential clustering within multi-strain
infections in young children, and identify individual amino acid positions that may contribute
to strain-speciﬁc immunity. Our results demonstrate that natural host defenses to
P. falciparum act in an allele-speciﬁc manner to block speciﬁc parasite haplotypes from
establishing blood-stage infections. This selection partially explains the extreme amino acid
diversity of many parasite antigens and suggests that vaccines targeting such proteins should
account for allele-speciﬁc immunity.
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P lasmodium falciparum, the most deadly of the humanmalaria parasites, has been co-evolving with its human hostfor at least tens of thousands of years1. Over this time
frame, the interactions of parasite, vector, and host have left
signatures of strong selection on both human and P. falciparum
genomes2–4. These evolutionary marks inform our understanding
of how P. falciparum successfully invades multiple host and
vector tissues while avoiding immune clearance. In turn, this
knowledge can be used to develop novel ways of disrupting the
P. falciparum transmission cycle. For instance, the high poly-
morphism of certain parasite proteins reﬂects their status as
immune targets, suggesting that a vaccine composed of the same
proteins could similarly elicit an effective immune response and
impede infection.
Whole-genome sequencing on a population scale has used
signatures of directional or balancing selection to identify
immunogenic P. falciparum genes as potential vaccine candi-
dates5. While these studies are useful for initially marking genes
of interest, such population genetic analyses provide a relatively
coarse-grained view of evolution; they identify the composite
signals of diverse intra- and inter-host selection pressures, not
selection directly mediated by individual vectors or hosts. To
better inform therapeutic efforts, we would ideally decouple these
various selection pressures by studying selective pressures
imposed during different life-cycle stages in isolation.
Here, we describe a high-resolution approach for studying host
interactions with P. falciparum, using high-depth sequencing of
PCR amplicons and population genetic approaches that treat each
infection as a discrete parasite population. In regions of high
parasite prevalence, malaria infections often contain multiple
haploid lineages of this sexually reproducing eukaryote. We
investigate signatures of within-host selection on these parasite
populations by using targeted deep population sequencing of
three highly polymorphic genes that are known targets of B-cell
or T-cell mediated immunity: CSP, TRAP, and SERA26–9. CSP
and TRAP are highly expressed by sporozoites10, the form of the
parasite that is injected into the human host by the mosquito and
invades the host liver. In contrast, SERA2 is a member of the
serine repeat antigen gene family, and like its homologs, is
expressed during the disease-causing blood-stage of the parasite
life cycle. Therefore, while all antigenic, these genes likely
experience different selection regimes due to their divergent
expression patterns across the P. falciparum life cycle (Fig. 1).
CSP and TRAP are both vaccine development targets. The utility
of SERA2 as a vaccine construct remains unexplored, but its high
polymorphism across sub-Saharan Africa suggests that host
immune recognition of this protein may affect parasite ﬁtness11.
In addition, this high polymorphism facilitates analysis of intra-
host dynamics by allowing us to differentiate a large number of
unique haplotypes.
Several previous studies have examined the population-level
diversity of CSP and TRAP12–21. These genes exhibit high levels
of non-synonymous polymorphism in sub-Saharan Africa, and
TRAP, in particular, has generally shown consistent evidence of
strong selection (but see Barry et al18.). Several studies have
documented functional evidence that natural and vaccine-
mediated human immune responses differentially recognize
variant CSP peptides11,22,23. Resolving the extent and nature of
allele-speciﬁc immune recognition of these and other
P. falciparum antigens would greatly aid the development of
effective next-generation malaria vaccines. To date, however,
observations of amino acid diversity have not been readily
translated into an increased understanding of immune function.
One complicating factor is that CSP and TRAP perform essential
functions in both the mosquito vector and human host24.
Ascribing selective pressures and functional constraint exclusively
to the human host calls for an approach that decouples the
selection imposed at these two distinct life-cycle stages.
Immune selection on P. falciparum is complex; the parasite has
developed numerous immune evasion strategies25 and natural
immune protection against malaria is mediated by recognition of
a large number of antigens26. Dissecting host immune recogni-
tion with an evolutionary approach therefore requires a strategy
capable of detecting relatively small selection coefﬁcients through
deep sampling of both the host and parasite populations. Multi-
lineage P. falciparum infections are commonly characterized
using small panels of putatively neutral SNPs27, microsatellite
markers28, or size-length polymorphisms29,30. These approaches
can quantify the number of clonal lineages within an infec-
tion31,32, but are of limited use for understanding the mechanics
of within-host selection. Whole-genome shotgun sequencing has
begun to provide information at the nucleotide level33–35, but the
predominance of host DNA in clinical samples limits the depth of
parasite genome sampling. This means that low frequency var-
iants within an infection are likely missed, constraining the use of
these datasets to questions involving large selection coefﬁcients.
In this study, we use deep sequencing of PCR amplicons to
proﬁle the parasite lineages in over 1600 infections. This
approach provides unprecedented power to detect selection
events (in the form of blocked infections) with small effect sizes
via the capacity to resolve the phasing of variants into haplotypes
representing distinct lineages. We show evidence of host-imposed
selection occurring at both the sporozoite/liver stage and the
blood stage of infection. Additionally, despite the large number of
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Fig. 1 Schematic representation of CSP, TRAP, and SERA2 expression proﬁles. The three genes have contrasting expression patterns that affect the source
and duration of the selection pressures they experience. CSP and TRAP are among the most abundantly expressed proteins in the sporozoite stage10.
SERA2 expression is highest during the blood stage and is in the 50th percentile of genes expressed in schizonts65
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antigens that drive acquired immunity to malaria, we are able to
point to speciﬁc amino acid positions that show a high probability
of mediating allele-speciﬁc host recognition within two of these
individual antigens, suggesting that the impact of acquired
immunity on parasite ﬁtness and infection outcome can be dis-
sected with high-resolution genomic data.
Results
High population-level diversity suggests immune selection.
Genes that experience immune selection are likely to exhibit high
levels of non-synonymous polymorphism and site frequency
spectra that indicate the action of balancing or diversifying
selection. Both of these expectations hold for our three focal
genes: CSP, TRAP, and SERA2 (Table 1). To obtain a picture of
these three genes in the context of genome-wide diversity pat-
terns, we analyzed whole-genome P. falciparum sequence data
from single-lineage infections in Senegal (n= 99) and Malawi (n
= 110). All three of the focal genes are among the 5% most
polymorphic genes in both populations, with CSP and TRAP
being among the top 1%. The regions selected for amplicon
sequencing display even higher levels of polymorphism than the
full genes (Fig. 2a). Relative to other coding regions in the P.
falciparum genome, the site frequency spectra of these genes and
amplicon regions are skewed toward having a high proportion of
intermediate-frequency SNPs, as measured by Tajima’s D, indi-
cative of diversifying selection. TRAP, as well as the regions of the
TRAP and CSP genes chosen for amplicon sequencing, are within
the upper 95th percentile of both populations’ Tajima’s D dis-
tributions (Fig. 2b). The genes, however, do not show evidence of
extensive adaptation to speciﬁc geographic locations or host
populations. None of the genes showed notable inter-population
divergence as measured using FST, and each amplicon region
showed lower population differentiation than its corresponding
full gene (Fig. 2c).
PCR-based amplicon sequencing was conducted on infection
samples collected across ﬁve study sites in the context of a clinical
vaccine trial (RTS,S/AS01)11. Each amplicon was composed of
~300 nt of contiguous sequence, acquired from overlapping
Illumina MiSeq read pairs. On average, thousands of reads were
sequenced per amplicon per sample, providing a more ﬁne-
grained view of nucleotide diversity within the three focal genes.
These data reveal a number of low frequency variants that were
not detected in previous sequencing studies, but the overall
patterns of polymorphism across the ﬁve study sites were
consistent with what was observed in the Senegal and Malawi
data (Table 2). The CSP amplicon contains three regions of high
amino acid diversity11 that include two previously described T-
cell epitopes (Th2R and Th3R)8 and a B-cell epitope (DV10)7.
These epitopes physically co-localize to one side of the folded
protein and surround a conserved hydrophobic pocket with
extremely low amino acid diversity36,37. For the TRAP and SERA2
amplicons there are no available protein structures, but their
patterns of diversity are similar to CSP, showing discrete stretches
of high diversity linked by regions with few or no variants (Fig. 3).
As observed in the genome-wide data, population differentia-
tion (FST) between the western and eastern African study sites is
not unusually high for any of these amplicons, although there are
a few individual variant sites that show reasonably high
population differentiation (Supplementary Data 1−3). Interest-
ingly, the two most diverse nucleotide sites in CSP (nt965 and
nt952) show little population differentiation. These positions
respectively contain four and three segregating nucleotides, and
both have a pairwise nucleotide diversity (π) above 0.6 in all ﬁve
study sites. Still, all population pairs show an FST under 0.01 at
both positions suggesting they experience similar selection
pressures at all geographic locations.
Because it provides haplotypic information, the amplicon
sequencing approach also allows for an analysis of linkage
disequilibrium (LD), or the preferential association of speciﬁc
allelic variants on the same genetic background. We found that
LD is highest for CSP and lowest for SERA2 (Fig. 4; Supplemen-
tary Fig. 1). While previously noted in the Th2R and Th3R
regions, we found that this LD extends to the DV10 region as
well. Interestingly, LD in CSP exists both within and between
known antigenic regions. Compared to TRAP and SERA2, this
level of LD is high given the genetic distance between these
regions (Supplementary Fig. 2) and cannot be attributed to recent
mutations and the expansion of a single haplotypic background
(Supplementary Data 4). Previous work has found no evidence
that intra-molecular forces drive the skewed association of alleles
at speciﬁc amino acid positions on CSP haplotypes13. This
suggests that the maintenance of preferred allelic combinations at
these positions might reﬂect the action of protein–protein
interactions, which could include antibody recognition of
conformational epitopes. The lower levels of LD found in TRAP
and SERA2 suggests that these proteins may experience fewer
structural constraints or be subject to immune recognition
through linear rather than conformational epitopes.
Intra-infection diversity reﬂects host selection. The majority of
infections sequenced with the amplicon approach contained
multiple haplotypes (CSP: 60.0%; SERA2: 53.6%; TRAP: 53.0%;
Table 1 Population genetic statistics for CSP, TRAP, and SERA2 calculated using genome-wide sequencing data
CSP TRAP SERA2
Full gene Amplicon region Full gene Amplicon region Full gene Amplicon region
Nucleotide diversity
Senegal 0.00601 (99) 0.0204 (99) 0.0102 (99) 0.0122 (99) 0.00191 (96) 0.00888 (99)
Malawi 0.00806 (99) 0.0211 (99) 0.0102 (99) 0.0132 (99) 0.00198 (96) 0.00894 (99)
Non-synonymous nucleotide diversity
Senegal 0.00674 (99) 0.0254 (99) 0.0120 (99) 0.0137 (99) 0.00181 (96) 0.0120 (99)
Malawi 0.00713 (99) 0.0263 (99) 0.0120 (99) 0.0144 (99) 0.00197 (97) 0.0119 (99)
Tajima’s D
Senegal −1.39 (78) -0.132 (96) 0.536 (98) 0.298 (98) −1.21 (84) −0.494 (94)
Malawi −0.765 (94) 0.519 (99) 0.712 (99) 0.257 (99) −1.24 (89) −0.868 (94)
FST
Senegal–Malawi 0.0512 (89) 0.0163 (57) 0.0576 (91) 0.0322 (80) 0.0236 (71) 0.00716 (22)
Genome-wide percentiles are given in parentheses
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Supplementary Fig. 3). We wished to determine whether these
polyclonal infections were composed of haplotypes drawn at
random from the population, or if selection was acting to group
similar (or dissimilar) haplotypes together. Such selection could
have occurred within the observed infection, or, as Hastings38
demonstrated, could represent the cumulative effect of past
selection events across multiple hosts as haplotype associations
can be maintained through stable co-transmissions between
individuals. To test for the presence of selection, we simulated a
set of 10,000 replicate datasets via bootstrapping of the pooled
haplotypes from each study site (Fig. 5). We could not determine
whether natural infections contained multiple parasite lineages
with identical haplotypes, so we ensured that the simulated
infections did not contain duplicate haplotypes. We then calcu-
lated the within-infection diversity of each infection and asked
whether haplotypes within observed infections were more similar
to one another than haplotypes in simulated infections. Our
metric of diversity is based on a population genetics framework
and depends on the number of distinct alleles at each variant
amino acid position within each infection. As shown in Fig. 5, the
number of alleles at a given amino acid position can differ from
the infection haplotype count since distinct haplotypes may share
the same allele.
We found that observed within-infection amino acid diversity
was lower than expected for all three genes across the ﬁve study
sites (Student’s t-test with Fisher’s combined P, P= 0.0183 (CSP),
P= 0.0123 (TRAP), and P= 0.0219 (SERA2)). Selection, however,
does not need to be evoked to explain this pattern; a reduction in
observed heterozygosity is also expected under a model of
population sub-division (the Wahlund effect). While we earlier
observed that population differentiation is relatively low between
study sites (Fig. 3), P. falciparum populations are known to
contain microstructure at the level of a household or village39,
which could contribute to protein-wide reductions in within-
infection diversity. However, while population sub-structure
would cause an overall decrease in heterozygosity across the
given protein, the change in heterozygosity at any individual site
would ﬂuctuate more widely. We, therefore, looked for amino
acid variants that showed decreased within-infection heterozyg-
osity across all ﬁve geographic sites. This pattern would suggest
the consistent action of selection rather than the random effects
of genetic drift operating on structured sub-populations.
Across all three amplicons, ﬁve amino acid positions showed
statistically signiﬁcant reductions in diversity (Fig. 6). Interest-
ingly, the amino acid position identiﬁed in CSP (aa354) is one of
the seven amino acid positions that showed signiﬁcant differential
protective efﬁcacy in a phase 3 trial of the malaria vaccine RTS,S/
AS0111. In Neafsey et al.,11 this was observed as a vaccine-
induced effect that manifested as greater protection against
infection by parasites harboring a CSP haplotype matching the
vaccine construct in RTS,S/AS01-vaccinated individuals. In this
study, we limit our analysis of CSP to individuals who were
enrolled in the control arm of the trial and therefore only detect
the effects of natural immunity. Combined, these studies provide
two independent lines of evidence suggesting that this amino acid
position is recognized in an allele-speciﬁc manner by an adaptive
B- and/or T-cell response.
Given past evidence that speciﬁc haplotypic combinations
enhance parasite infectivity40, we also considered the inverse
question: do certain genotypes preferentially associate within
infections? Only one amino acid position (CSP aa301) showed
evidence of increased within-infection heterozygosity. As with
CSP aa354—which showed increased within-host homozygosity
—CSP aa301 was identiﬁed by Neafsey et al11. as showing an
effect of allele-speciﬁc vaccine efﬁcacy in the RTS,S/AS01 vaccine
trial. One of the nucleotide positions coding for this amino acid
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Fig. 2 Genome-wide signatures of P. falciparum polymorphism in Senegal
and Malawi. a CSP, TRAP, and SERA2 show unusually high levels of non-
synonymous nucleotide diversity. b TRAP, the TRAP amplicon region, and
the CSP amplicon region have unusually high Tajima’s D values. c None of
the genes or amplicon regions show strong population differentiation (FST).
Each point represents the coding sequence from a single protein-coding
gene. Solid and dashed lines mark the 95th and 99th percentiles,
respectively. Focal genes are marked with ﬁlled symbols: CSP (circle), TRAP
(square), SERA2 (triangle). Full genes are colored blue, whereas the regions
selected for amplicon sequencing are colored red
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(nt902) is also the CSP nucleotide position with the highest
divergence (FST) between western and eastern African study sites.
Overall, however, the relatively low number of sites showing
increased heterozygosity suggests that immune interference does
not widely contribute to changes in infection diversity—at least
not at the level of individual amino acid variants. Instead, the
stronger evolutionary force in these populations appears to be
allele-speciﬁc selection against particular genotypes, leading to an
overall decrease in within-infection diversity.
SERA2 amino acid diversity is lower in older patients. The
above analysis suggests that either the host or mosquito vector
causes infections to be selectively assembled. To further test the
hypothesis that selection is speciﬁcally exerted by adaptive
immune responses, we investigated how infection diversity relates
to a known correlate of immune competence: patient age. In
malaria-endemic countries, adults do not acquire full immunity
to malaria infection41, but the parasite levels in their blood are
signiﬁcantly reduced compared to the levels in young children,
and they are less likely to develop clinical malaria42. The acqui-
sition of adaptive immune defenses plays a role in this age-
dependent disease resistance43, although the exact mechanism
remains unclear. Our dataset offers an opportunity to examine
the effects of age-related immune acquisition on a nucleotide
level. To do so, we make two assumptions: (1) hosts mount more
effective immune responses against parasite haplotypes to which
they were previously exposed; and (2) patient age positively
Table 2 Summary of nucleotide variants described with targeted amplicon sequencing
Amplicon region
(amplicon length)
Sampled
infections
Sequenced
amplicons
Total variant
sites
Nonsyn.
variant sites
Singleton
variants
Common
variantsa
Highly variant
sitesb
CSP (288 nt)
Total 1687 3821 55 50 15 23 12
West Africa 935 2147 46 43 8 24 8
East Africa 752 1674 41 39 8 23 8
TRAP (318 nt)
Total 4209 8774 52 52 13 15 5
West Africa 2334 4925 38 38 7 16 5
East Africa 1875 3849 38 38 10 15 3
SERA2 (258 nt)
Total 4209 9007 67 67 19 12 16
West Africa 2334 5048 53 53 17 13 12
East Africa 1875 3959 49 49 11 8 11
a Minor allele frequency >0.02
b >2 segregating alleles
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Fig. 3 Nucleotide diversity and population differentiation within CSP, TRAP, and SERA2 as measured with amplicon sequencing. a Graphs of pairwise
nucleotide diversity (π) present the mean ± 1 S.D. across all ﬁve study sites. b Graphs of population differentiation show the mean ± 1 S.D. of pairwise FST
values between western and eastern study sites. Statistics were calculated using SNPs within overlapping 10-nt windows with a step size of 5 nt. The
colored bars in the CSP graph mark three previously identiﬁed regions of high diversity: DV10 (blue), Th2R (green), and Th3R (yellow)
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correlates with cumulative exposure to P. falciparum. Under this
model, successful infection blocking would be haplotype-speciﬁc
and more frequent in older relative to younger children. This
would lead to lower infection diversity in the former relative to
the latter group at amino acid positions that are effective immune
targets.
To test if patient age correlates with P. falciparum infection
diversity, we constructed a quasi-Poisson model that accounted
for additional factors including study site, complexity of infection,
and type of sampling (active vs. passive). For SERA2, but not CSP
or TRAP, we found a negative effect of patient age on within-
infection amino acid diversity (−0.032 mismatches per year,
quasi-Poisson model, P= 0.028; Table 3). Across the SERA2
amplicon, mean number of pairwise differences per infection was
2.907. This suggests that as children age by one year, the amino
acid diversity at SERA2 reduces by ~1.1%.
We next modeled diversity at individual amino acid positions
within each amplicon. Diversity at two amino acid positions in
SERA2 (aa93 and aa95) showed nominally signiﬁcant age effects
(aa93: −0.12 mismatches per year, quasi-Poisson model, P=
0.047; aa95: −0.39 mismatches per year, quasi-Poisson model, P
= 0.032), but their statistical signiﬁcance did not survive
multiple-testing correction. Overall, therefore, this result suggests
that the reduction in amplicon-level diversity cannot be attributed
to the effect of a single amino acid site. This is consistent with a
model where immune recognition at this antigen occurs at
multiple sites rather than at a single amino acid position. Future
studies incorporating longitudinal sampling of individual hosts
could resolve whether different hosts preferentially recognize
different amino acid positions within this antigen.
Given that SERA2 is expressed during the protracted blood-
stage, this observation is consistent with evidence that natural
acquired immunity most strongly controls P. falciparum
transmission at the blood-stage of infection44. Detection of this
trend in young children (<5 years of age) suggests that acquired
immune defenses likely begin building at an earlier age than
previously observed in clinical studies44. These defenses, however,
may not yet be sufﬁcient to cause measurable reductions in
disease incidence.
Discussion
Targeted deep sequencing of pathogen genes provides a powerful
and efﬁcient way to gain insight into host–pathogen interactions.
The amino acid positions we identify with this approach may
mediate allele-speciﬁc immune responses to P. falciparum anti-
gens, including the leading vaccine component CSP. While we do
not know the extent to which parasite antigens are or are not
cross reactive, several recent vaccine candidates—all monovalent
subunit vaccines developed from single P. falciparum genotypes—
have displayed allele-speciﬁc protection11,45. In light of these
observations, one proposed course of action is the development of
multivalent vaccines that target multiple pathogen genotypes46.
By identifying speciﬁc amino acid positions that likely contribute
to differential recognition, we provide key information for the
development of such next-generation vaccines. Further, we
illustrate that vaccine development challenges will be antigen-
speciﬁc: due to a combination of protein function and expression
pattern (Fig. 1), each protein experiences distinct selection pres-
sures and structural constraints that create unique signatures of
diversity, divergence, and LD.
While previous genetic analyses have provided evidence that
CSP is under selection in the human host12–16, few have provided
actionable information on speciﬁc amino acid positions that may
mediate natural host–pathogen interactions. One important
exception is Gilbert et al40., who studied within-host haplotype
diversity of the CSP T-cell epitope Th3R. Like this study and
Neafsey et al11., they found that alleles at CSP amino acid
354 show preferential associations within infections. Interestingly,
however, their samples showed the opposite effect of the one
observed here. In our study, diversity at aa354 is lower within
hosts than would be expected. Conversely, Gilbert et al40. found
that two 8-aa haplotypes (cp26 and cp29) that differed only at
aa354 showed the propensity to co-occur within infections,
thereby increasing diversity at this single amino acid position.
Additional in vitro studies found that these two haplotypes acted
in concert to evade immune detection through a process of
immune interference, thereby increasing their combined ﬁtness47.
In our samples, one of these haplotypes was at too low of a
frequency to assess its potential preferential associations. Thus,
the diversity changes we observed at aa354 were independent of
the 8-aa haplotypes described by Gilbert et al40. The opposing
directions of the effects noted across studies suggests that non-
additive interactions between alleles can determine the course of
selection on any individual site, reinforcing the need to consider
extended haplotype information and patterns of LD when
studying immune recognition of P. falciparum antigens.
As we demonstrate here, population-level and host-level
approaches provide complementary information that together
identify not only genes, but also speciﬁc amino acid positions of
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immunological and evolutionary interest. Gene-level statistics like
Tajima’s D can mask relevant intra-gene patterns, especially when
genes include constrained functional elements. Similarly,
population-level analyses average selection pressures across
multiple life stages and multiple human hosts. By focusing on a
single life stage, we ﬁnd evidence for there being amino acid
positions under selection within CSP and SERA2—genes that do
not show signiﬁcant evidence for selection in a traditional
population-level genome-wide analysis. In this regard, there are
parallels between the analysis we present here and approaches,
such as selection components analysis48 and single-cell sequen-
cing. In essence, these are all ways of dissecting a single composite
signal to better understand the distinct forces or dynamics
underneath. This added granularity helps assign causality and
identify targets of selection that may be masked by averaging
signals across loci, hosts, or life stages.
The utility of targeted amplicon sequencing therefore extends
beyond questions of immune selection. There is growing recog-
nition that intra-host dynamics must be considered when
studying diverse aspects of Plasmodium biology, including drug
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resistance49,50, disease severity51–54, and transmission rate55,56.
Our observations show that human-mediated selection on P.
falciparum is sufﬁciently strong to be detected using measures of
within-infection diversity and demonstrate the utility of incor-
porating evolutionary approaches into Plasmodium studies. Tar-
geted deep sequencing of genes involved in additional biological
processes can further augment current efforts to understand and
manipulate the interactions between humans and this complex
parasite.
Methods
Filtering and analysis of genome-wide sequence data. To place our amplicon
sequences within a genome-wide context, we obtained genome-wide variant calls
for P. falciparum samples collected in Senegal57 (n= 137) and Malawi19 (n= 269)
from the Pf3k project (release 5; www.malariagen.net/projects/pf3k). Variant calls
were downloaded as vcf ﬁles, and only variable sites that were ﬂagged as passing all
GATK ﬁlters were retained. We further limited the analysis to variant sites that fell
within coding regions and used SnpEff calls to annotate each variant as synon-
ymous or non-synonymous. To accurately calculate population-level allele fre-
quencies, we identiﬁed samples that likely contained only single P. falciparum
clones. Plasmodium is haploid throughout its human-infecting life stages. Het-
erozygous calls therefore signal either alignment errors or the presence of multiple
co-occurring genetic lineages within a sample. For each sample, we calculated the
fraction of variant sites across all genes that were heterozygous or missing. Samples
with either ≥2% heterozygous calls or ≥4% missing calls were removed from the
analysis. To prevent this calculation from being dominated by poorly aligned genes,
we ﬁrst masked a set of 243 genes where 20% or more samples had either ≥25%
heterozygous calls or ≥25% missing calls. This left us with a set of 99 Senegal and
110 Malawi samples that likely contained a single P. falciparum genotype (Sup-
plementary Data 5). All downstream analysis was limited to this set of 209 single-
clone infections. After identifying these single-clone samples, we returned the
previously masked genes to the dataset and re-calculated population-level diversity
for each gene. We found 315 genes that had either ≥20% heterozygous calls or
≥20% missing calls in these samples. As these were single-clone samples, high levels
of intra-sample heterozygosity or missing data likely signaled alignment errors, not
true intra-host variants. We therefore masked these 315 genes from the analysis.
We transformed any remaining heterozygous calls into homozygous calls by
retaining only the allele with greatest read support. Only SNP calls were retained
for use in downstream analyses.
For each gene, we calculated two measures of nucleotide diversity (π and
Watterson’s θ), Tajima’s D, and Weir and Cockerham’s estimate of FST58 using
custom Perl scripts (available on request). Sites with more than two alleles were
retained and counted as multiple segregating sites when calculating Watterson’s θ.
The numerator and denominator of the FST statistic were averaged individually
across sites in a given gene. At each site, we adjusted the sample size based on the
number of samples with successful calls. We assumed that all sites without called
variants were reference alleles for all the samples. For each gene, statistics were
calculated across all sites, at synonymous sites only, and at non-synonymous sites
only. To ensure we were not biasing our results by using genes with little coverage,
we limited our analysis to 3682 genes that had at least ﬁve SNPs in one of the
populations.
Filtering and analysis of targeted amplicon sequences. The amplicon sequences
for CSP (PF3D7_0304600), TRAP (PF3D7_1335900), and SERA2
(PF3D7_0207900) were previously generated and ﬁltered by Neafsey, et al11. The
CSP amplicon covers the diverse C-terminal region of the CSP gene, which forms a
large portion of the RTS,S vaccine construct (Pf3D7_03_v3:221352.221639)59. The
TRAP and SERA2 amplicons were designed to capture regions of high diversity
within these respective genes (Pf3D7_13_v3:1465059.1465376;
Pf3D7_02_v3:320763.321020). Parasite DNA was obtained from blood samples
acquired as part of the RTS,S/AS01 vaccine phase 3 trial60. In brief, children
(5–7 months of age) and infants (6–12 weeks age) were randomly assigned to one
of two arms of the vaccine trial. Approximately two-thirds received the RTS,S/AS01
vaccine regimen whereas one-third received a control rabies vaccine. Blood samples
included both passive and active sampling. Passive clinical samples were collected
from febrile children with at least 5000 parasites/μl at the time of ﬁrst clinical
malaria infection occurring within the ﬁrst 12 months following completion of the
triple-dose vaccination regimen. Active cross-sectional sampling occurred in a
subset of participants at 18 months post-vaccination. Samples were stored as dried
blood spots until DNA extraction. Targeted regions were then ampliﬁed and
sequenced using overlapping 250-bp paired-end reads with Illumina MiSeq tech-
nology. Paired-end reads were merged using FLASH61 and aligned to the Plas-
moDB v.9.0 3D7 P. falciparum reference genome using BWA v.0.7462.
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Fig. 6 Deviation from expected within-host diversity at individual amino acid positions within the CSP, TRAP, and SERA2 amplicon regions. Points above the
dotted line mark amino acid positions with signiﬁcant heterozygosity differences between observed and simulated infections after Bonferroni correction.
Filled circles show a reduction in observed within-infection diversity whereas open circles show an increase in observed within-infection diversity. The size
of the point corresponds to the effect size estimated with a quasi-Poisson regression. Points in red show a marginally signiﬁcant effect of age on diversity
(P < 0.05) before multiple-testing correction, but none of these interactions remain signiﬁcant after Bonferroni correction. Only variant positions with a
major allele frequency <0.98 were included in the analysis
Table 3 Parameter estimates from quasi-Poisson regression model of within-host infection diversity
CSP TRAP SERA2
Variable Effect estimate P Effect estimate P Effect estimate P
Patient age (in years) 0.0094 n.s. 0.015 n.s. −0.032 0.028
Sample typea −0.033 n.s. 0.016 n.s. 0.072 0.0015
Haplotype number 0.011 n.s. -0.012 0.035 -0.0020 n.s.
a Longitudinal, asymptomatic sampling vs. clinical infection sample
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This targeted amplicon approach allowed the identiﬁcation of complete, linked
haplotypes across the sequenced regions. To minimize the misidentiﬁcation of
spurious haplotypes within samples, Neafsey, et al11. adopted a set of conservative
ﬁlters that removed the following: (1) all reads with uncalled bases; (2) sequences
representing fewer than 1% of the reads in a given sample; (3) haplotypes observed
only once in the entire dataset that were represented by fewer than 500 reads. After
ﬁltering, haplotypes within each sample were clustered. If two haplotypes differed
by only 1 nucleotide (nt) and their read ratio was less than 0.15, the haplotypes
were merged. All samples with more than two haplotypes following clustering and
ﬁltering were evaluated for PCR chimerism. If a haplotype could be expressed as a
simple combination of two other haplotypes called for the same sample and was
supported by fewer than 250 reads, it was eliminated from the ﬁnal dataset. After
merging and ﬁltering, the median read count per sample was still very high (CSP:
5559, TRAP: 3001, SERA2: 4912).
For the purposes of this study, we used data from the ﬁve study locations with
the highest transmission intensities: Kintampo, Ghana; Agogo, Ghana; Nanoro,
Burkina Faso; Kombewa, Kenya; and Siaya, Kenya. In total, this provided
information on 4209 infections: 2522 from RTS,S/AS01-vaccinated and 1687 from
control-vaccinated individuals. Analyses of CSP used only data from the control-
vaccinated individuals. After conﬁrming that the RTS,S/AS01 vaccine had no effect
on diversity at the TRAP and SERA2 amplicons, we included all patient samples in
analyses of these genetic regions.
Population genetic and statistical analyses. For each study site, we calculated
pairwise nucleotide diversity (π) and Weir and Cockerham’s measure of population
differentiation (FST;58) at each SNP and within 10 nt windows across each
amplicon region. We calculated LD between pairs of sites—including sites with
more than two variants—using Lewontin’s D’63 and Hedrick and Thomson’s Q*64.
To test for the effect of age on within-infection amino acid diversity, we
constructed a quasi-Poisson regression model with patient age at time of infection,
study site, sample type (passive/clinical, active/cross-sectional), and haplotype
number as ﬁxed effects. Within-infection diversity was modeled separately for each
amplicon. Models were constructed to study infection diversity on the level of the
whole amplicon and on the level of individual amino acid positions. The analysis
was conducted in R with the glm function.
Modeling expected infection heterozygosity. Within our sample of 4209
infections, we recovered 0–13 haplotypes per amplicon per infection, with over
50% of infections containing multiple segregating P. falciparum genotypes.
Infection diversity is dependent on COI, so we determined the expected level of
infection diversity through bootstrapping. For each study site, we created a
haplotype pool that contained the exact number of each haplotype recovered
during sequencing. We then created 10,000 sets of simulated infections that
maintained the same COI structure observed in each population but where the
infecting strains were sampled with replacement from the haplotype pool (Fig. 5).
As we were not able to differentiate identical haplotypes in the natural infections,
each simulated infection was similarly constrained to contain only unique
haplotypes.
For each sample (both observed and simulated), we calculated within-infection
amino acid diversity for the full length of each amplicon as the mean number of
differences between each pairwise haplotype comparison within the sample. When
analyzing diversity at individual positions, we counted the number of haplotype
pairs that mismatched at the given site. To determine whether mismatches were
more or less frequent in the observed vs. the simulated infections at a given amino
acid position, we constructed a quasi-Poisson regression model that included
dataset (observed, simulated), haplotype number, study site, sample type (passive/
clinical, active/cross-sectional), and age group (infant, child) as ﬁxed effects. We
additionally included two interaction terms: (dataset × sample type) and (dataset ×
age group). These accounted for the possibility of increased acquired immunity in
older children and for potential differences between symptomatic and
asymptomatic infections. The Bonferroni correction was performed to account for
multiple testing across multiple sites within each individual gene. Variant sites were
only analyzed if they were polymorphic in all ﬁve populations and had a global
major allele frequency under 0.98. For the simulated data, we included results from
1000 bootstrapped datasets. The analysis was conducted in R with the glm
function.
Data availability. All raw Illumina reads from the original Neafsey et al11. study
are available on the NCBI Short Read Archive (BioProject PRJNA235895 [https://
www.ncbi.nlm.nih.gov/bioproject/?term= PRJNA235895]). Supplementary Data 6
and 7 contain the ﬁnal called haplotypes and metadata from children and infants
enrolled in the control arm of the vaccine trial.
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